Melphalan
Overview
Melphalan is a bifunctional alkylating agent used in the treatment of multiple myeloma and other types of cancer. It works by causing cross-links in the DNA, leading to cell death.
API suppliers (6)
Suppliers of Melphalan evidenced by a US FDA Type II Drug Master File or an EU Certificate of Suitability (CEP). Sources: FDA DMF list, EDQM certification database.
Country recorded for 3 of 6 suppliers.
1 of 6 holds a GMP certificate on record in the EU or UK registers
- CHEMWERTH INCFrance1 active DMF
- NERPHARMA SRLItaly1 active DMF GMP on record
- SHILPA PHARMA LIFESCIENCES LTDIndia1 active DMF
- HUBEI HONCH PHARMACEUTICAL CO LTD1 active DMF
- BIOPHORE INDIA PHARMACEUTICALS PVT LTD1 active DMF
- XIAN LIBANG PHARMACEUTICAL CO LTD
Patent & exclusivity (US)
Per the FDA Orange Book (15 approved US products), the latest listed US patent on Melphalan expires 29 Jun 2036 and exclusivity 14 Aug 2030. Generic API sourcing typically opens up once these lapse.
Therapeutic areas
Do you supply Melphalan? Get in front of buyers actively sourcing it.
We route real sourcing requests from pharma buyers to vetted, verified partners — qualified leads, not just a listing. Tell us what you make and we'll be in touch about becoming a Verified Supplier Partner.
Ready to Accelerate Your
Discovery Workflow?
Find, vet, and source drug-manufacturing partners faster — with FDA compliance screening built in. Start free for 7 days.